<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	.wrap { overflow:hidden; }
	.content h2 { margin-bottom:30px; }
	[data-slide='4'] .feature, [data-slide='7'] .feature { float:right; width:605px; height:425px; }
	[data-slide='4'] .feature { background-image:url(img/graph-lines.png); }
	.indicator { width:322px; position:relative; }
	.indicator, .indicator i { float:left; }
	.indicator > li, .indicator i em { font-family:interstateregular-condensed; }
	.indicator > li { font-size:20px; line-height:23px; background:rgba(0, 77, 116, 0.15); padding:20px; margin-bottom:14px; margin-top:180px; }
	.indicator li:first-child { margin-top:0; width:282px; position:absolute; top:0; left:0; padding-bottom:32px; }
	.indicator > li p { clear:left; font-size:16px; line-height:22px; font-family:interstatelight; margin-top:1.6em; display:none; }
	.indicator i { width:145px; min-height:110px; font-family:interstatebold-condensed; font-size:83px; line-height:83px; letter-spacing:-0.02em; }
	.indicator :last-child > i { letter-spacing:-0.045em; }
	.indicator em { font-style:normal; font-size:0.95em; }
	.indicator .arrow { width:30px; font-family:interstatebold; top:auto; bottom:-2px; left:auto; right:4px; }
	.indicator .arrow:before { font-size: 26px; }
	.indicator .active { border-top:5px solid #b2d234; background:#004d74; color:#ffffff; }
	.indicator .less.arrow { transform: rotate(180deg); bottom:2px; }
	
	.label, .state, .state:after, .key { position:absolute; }
	.state { background:url(img/graph_state1.png) 0 0 no-repeat;  left:54px; opacity:0; }
	.state:after { content:""; left:0; background:url(img/graph_state2.png) 0 0 no-repeat; opacity:0; }
	.state3 .state { background:url(img/graph_state3.png) 0 0 no-repeat;  }
	#container .state, #container .state:after { width:556px; height:inherit; background-size:100% auto; }
	.key { width:595px; right:0; bottom:80px; } 
	.key li { font-family:interstatelightCon; font-size:14px; line-height:16px; margin-bottom:3px; padding:4px 15px 0; overflow:hidden; }
	.key li:first-child { font-family:interstateregular-condensed; border-bottom:1px solid rgba(0, 77, 116, 0.5); margin:0 0 4px 15px; padding: 0 0 1px; }
	.key li > span { float:left; width:17.1%;  }
	.key li > span:first-child { width:70px; text-align:left; }
	.key li > span:last-child { text-align:left; width:auto; }
	.key li:nth-child(n+2) { background: #99b7c7; color:#ffffff; }
	.state2 .key li:nth-child(2),
	.state3 .key li:nth-child(2) { background: #004d74; }
	.state1 .key li:last-child, 
		.state2 .key li:last-child,
		.state3 .key li:last-child{ background: #b2d234; }
	
	.label { right:0; top:0; font-size:13px; line-height:16px;}
	.label li { font-family:interstateregular; font-size:20px; line-height:22px; }
	.footnote.s10 { bottom:6px; width:709px; text-align:justify; font-size:10px; line-height:13px; }
	.footnote.s12 { bottom:155px; }
	/* states */
	.state1 .state, .state2 .state, .state2 .state:after, .state3 .state { opacity:1; }
	
	/* 5 */
	[data-slide='5'] .feature { width:820px; height:405px; background-image:url(img/study_19.png); margin-top:20px; }
	[data-slide='5'] p { margin-bottom:5px; }
	[data-slide='5'] .label { position:relative; top:10em; left:47px;  }
	[data-slide='5'] .label li { color:#ffffff; float:left; width:250px; font-size:16px; line-height:20px; font-family:interstateregular-condensed; }
	[data-slide='5'] li:last-child { width:200px; margin-top:-3.2em; }
	[data-slide='5'] li:last-child > span { margin-bottom:18px; }
	[data-slide='5'] li:last-child > span:nth-child(2) { margin-bottom:5px; }
	[data-slide='5'] .label li:first-child, [data-slide='5'] .label li > .rand { font-family:interstatebold-condensed; }
	[data-slide='5'] .label li:nth-child(2) { text-align:center; margin:-12px 77px 0 10px; color:inherit; } 
	[data-slide='5'] .label span { display:block; }
	[data-slide='5'] .label li:nth-child(2), 
		[data-slide='5'] li:last-child > span { font-size:17px; line-height:20px; }
	[data-slide='5'] .label li > .rand { font-size:12px; line-height:16px; margin: 12px 0; color:#ffffff; }
	[data-slide='5'] .label li i { color:#b2d234; }
	[data-slide='5'] .footnote { font-family:interstatelightCon; }
	
	/* 6 */
	[data-slide='6'] .feature { margin:20px 0 0; width:882px; height:405px; background-image:url(img/data.svg); }
	[data-slide='6'] .footnote { position:absolute; bottom:2px; left:0; }
	
	/* 7 */
	[data-slide='7'] .feature { background-image:url(img/graph-lines2.png); }
	[data-slide='7'] .indicator { width:277px; padding:20px; background:rgba(0, 77, 116, 0.15); }
	[data-slide='7'] .key li:nth-child(n+2) { padding:0; background:none; color:#004d74; }
	[data-slide='7'] .key li:last-child { color:#b2d234; }
	[data-slide='7'] .key li:first-child { margin-left:0; }
	
	
	
	.indicator li, .key li, .state, .state:after { -webkit-transition:all 0.5s ease; transition:all 0.5s ease; }
	
	
	
</style> 
</head>
<body>
	<section id="container">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
        	<!--subslides-->
            <div class="swiper-container">
                <ul class="swiper-wrapper">
                	<!-- slide 4-->
                    <li class="swiper-slide" data-slide="4">
                         <h2><span>CLINICAL DATA – EXTENDED PFS</span>
                            ADDING LYNPARZA TO THE TREATMENT PARADIGM ALLOWS WOMEN<br />
                            LIVING WITH BRCAm PLATINUM-SENSITIVE RELAPSED HIGH GRADE<br />
                            SEROUS OVARIAN CANCER TO ACTIVELY EXTEND PFS<sup data-ref="3">3</sup>
                        </h2>
                        <div class="wrap">
                            <ul class="indicator">
                                <li class="active"> <i><em>+</em>6.9</i>
                                    MONTH<br />
    IMPROVEMENT<br /> 
    IN MEDIAN PFS<br /> 
    OVER PLACEBO<sup data-ref="4">4</sup>
        <p>Maintenance treatment with<br />
    Lynparza has demonstrated a<br />
    significant benefit for BRCAm<br />
    platinum-sensitive relapsed ovarian<br />
    cancer patients, improving PFS by a<br />
    median of 6.9 months vs placebo.<sup data-ref="4">4</sup></p>
                                    <span class="icon arrow"></span>
                                </li>
                                <li class=""> <i>82<em>%</em></i>
                                    REDUCTION IN THE<br /> 
    RISK OF DISEASE<br /> 
    PROGRESSION OR<br /> 
    DEATH COMPARED<br /> 
    TO PLACEBO<sup data-ref="4">4</sup>
                                </li>
                            </ul>
                            
                            <div class="feature">
                                <span class="state"></span>
                                <span class="btn btn-play graph"></span>
                                <p class="label">HR 0.18 (95% CI 0.10-0.31); p&lt;0.00001;<br />median PFS 11.2 vs 4.3 months.<sup>4</sup></p>
                            </div>
                            <ul class="key">
                                <li>No. at risk</li>
                                <li>
                                    <span>LYNPARZA</span>
                                    <span>74</span>
                                    <span>59</span>
                                    <span>34</span>
                                    <span>15</span>
                                    <span>5</span>
                                    <span>0</span> 
                                </li>
                                <li>
                                    <span>PLACEBO</span> 
                                    <span>62</span>
                                    <span>35</span>
                                    <span>13</span>
                                    <span>2</span>
                                    <span>0</span>
                                    <span>0</span> 
                                </li>
                            </ul>
                        </div>
                        
                        <span class="footnote abs s12">Adapted with permission from Ledermann.<sup data-ref="3">3</sup></span>
                        
                        <div class="footnote abs s10">
                            <strong>Study design:</strong> This a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum- sensitive,
relapsed, high-grade serous ovarian cancer who had received two or more platinum based regimens and had a partial or complete response to their
most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point
was progression-free survival according to the Response Evaluation Criteria in Solid Tumours guidelines. Primary endpoint was PFS. Secondary endpoints
included OS, best overall response, HRQoL, safety and tolerability.
                        </div>
                       
                    </li>
                    <!-- slide 5 -->
                    <li class="swiper-slide" data-slide="5">
                         <h2><span>CLINICAL DATA – STUDY OVERVIEW</span>
                           STUDY 19 WAS A RANDOMISED, DOUBLE-BLIND,<br />
PLACEBO-CONTROLLED PHASE II CLINICAL TRIAL<sup data-ref="2">2</sup>
                        </h2>
                        <p>In Study 19, Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study
population.<sup data-ref="2">2</sup></p>
                        <div class="feature">
                        	<ul class="label">
                                <li>TOTAL STUDY platinum-sensitive
relapsed high-grade serous ovarian
cancer following complete or partial
response to prior platinum-based
therapy (N=265).<sup data-ref="2">2*</sup></li>
                                <li>Lynparza<br />
400 mg po bid
<span class="rand">Randomised 1:1<sup>2</sup></span>
Placebo<br />
po bid
</li>
                        		<li>
                                	<span>PRIMARY ENDPOINT:<br />
PFS<sup data-ref="4">4</sup></span>
<span>SECONDARY ENDPOINTS:</span>
<i>•</i> Overall survival<sup data-ref="4">4</sup><br />
<i>•</i> Disease control rate<sup data-ref="4">4</sup><br />
<i>•</i> Disease-related symptoms<sup data-ref="4">4</sup><br />
<i>•</i> Safety and tolerability
                                </li>
                        	</ul>
                        </div>
                        <p>A retrospective analysis was conducted on a pre-defined subgroup<br />
of patients with BRCA mutations. This is included 51% of patients N=136.<sup data-ref="3">3</sup></p>
<p class="footnote">*Platinum-sensitive defined by a relapse-free period of <span class="sym">≥</span>6 months following a rese final dose ponse to thof platinum-based chemotherapy treatment.</p>
                    </li>
                    <!-- slide 6 -->
                    <li class="swiper-slide" data-slide="6">
                         <h2><span>CLINICAL DATA – BRCAm SUB ANALYSIS</span>
                          PATIENTS WITH BRCAm PLATINUM-SENSITIVE RELAPSED HIGH GRADE
SEROUS OVARIAN CANCER EXPERIENCED THE GREATEST CLINICAL
BENEFIT WITH LYNPARZA<sup data-ref="2-3">2,3</sup>
                        </h2>
                        <p>A pre-planned subgroup retrospective analysis by BRCAm status identified patients with BRCAm ovarian cancer
(n=136, 51%) as the subgroup that derived the greatest clinical benefit from Lynparza maintenance monotherapy.<sup sup data-ref="3">3</sup></p>
                        <div class="feature"></div>
                        <p class="footnote">Adapted with permission from Ledermann.<sup data-ref="2">2</sup></p>
                    </li>
                    <!-- slide 7 -->
                    <li class="swiper-slide" data-slide="7">
                         <h2><span>CLINICAL DATA – BRCAm SUB ANALYSIS</span>
                          PATIENTS WITH BRCAm PLATINUM-SENSITIVE RELAPSED HIGH GRADE
SEROUS OVARIAN CANCER EXPERIENCED THE GREATEST CLINICAL
BENEFIT WITH LYNPARZA<sup data-ref="2-3">2,3</sup>
                        </h2>
                         <div class="wrap">
                         	<div class="indicator">
                            	In patients with a BRCA<br />
mutation, Lynparza delayed the<br />
time from randomisation to start<br />
of first subsequent therapy or<br />
death (TFST)*, or when patients<br />
needed their next chemotherapy,<br />
by a median of 9.4 months<br />
(H R 0.33; 95°/oC I 0.22-0.50;<br />
p&lt;0.0001; median 15.6 months<br />
vs 6.2 months).<sup sup data-ref="3-4">3-4</sup>
                            </div>
                            <div class="feature">
                                <span class="state"></span>
                                <span class="btn btn-play graph"></span>
                                <p class="label">HR 0.18 (95% CI 0.10-0.31); p&lt;0.00001;<br />median PFS 11.2 vs 4.3 months.<sup>4</sup></p>
                            </div>
                            <ul class="key">
                                <li>No. at risk</li>
                                <li>
                                    <span>LYNPARZA</span>
                                    <span>74</span>
                                    <span>59</span>
                                    <span>34</span>
                                    <span>15</span>
                                    <span>5</span>
                                    <span>0</span> 
                                </li>
                                <li>
                                    <span>PLACEBO</span> 
                                    <span>62</span>
                                    <span>35</span>
                                    <span>13</span>
                                    <span>2</span>
                                    <span>0</span>
                                    <span>0</span> 
                                </li>
                            </ul>
                        </div>
                        
                        <span class="footnote abs s12">Adapted with permission from Ledermann.<sup data-ref="3">3</sup><br />
*An exploratory retrospective analysis.</span>
                        <div class="footnote abs s10">
                            <strong>Study design:</strong> This a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinumsensitive,
relapsed, high-grade serous ovarian cancer who had received two or more platinum based regimens and had a partial or complete response to their
most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point
was progression-free survival according to the Response Evaluation Criteria in Solid Tumours guidelines. Primary endpoint was PFS. Secondary endpoints
included OS, best overall response, HRQoL, safety and tolerability.
                        </div>
                    </li>
                    
                </ul><!-- end swiper-wrapper -->
                <!-- Add Arrows -->
       			<span class="swiper-button icon arrow swiper-button-next"></span>
        		<span class="swiper-button icon arrow swiper-button-prev"></span>
            </div>
            
        	<span class="logo lynp"></span>
        </article>
    
    <!-- popup -->
    <div class="overlay shade">
    	<!-- reference -->
    	<div class="ref hide">
            <div class="item"> <span class="close icon"></span>
                <h1>References</h1>
                <ol></ol>
            </div>
        </div><!-- end ref -->
         <!-- info -->
        <div class="item info hide"><span class="arrow icon"></span>
            <ul class="list hide" datd-info="2">
                <li>Every day hundreds of thousands of dna lesions occur in cells, including single-strand breaks (SSBs).<sup data-ref="7">7</sup></li>
                <li>The enzyme poly ADP ribose polymerase (PARP) is a key protein required for the efficient repair of
these SSBs through a mechanism known as base excision repair (BER).<sup data-ref="8-9">8-9</sup></li>
                <li>When PARP function is inhibited, cells cannot effectively repair SSBs. As a result, these unrepaired
SSBs are converted to double strand breaks (DSBs) during DNA replication, requiring repair via the
homologous recombination pathway (HRR).<sup data-ref="10-11">10-11</sup></li>
            </ul>
            <!-- 3 -->
            <ul class="list hide" datd-info="3">
                <li>SSBs and DSBs are preferentially repaired by error-free mechanisms that utilise poly(ADP-ribose)
polymerase (PARP) and BReast CAncer susceptibility protein (BRCA)1/2 proteins, respectively.<sup data-ref="7-11">7-11</sup></li>
            </ul>
            <!-- 3b -->
      		 <ul class="list hide" datd-info="3b">
                <li>With both error-free repair mechanisms blocked, DNA can only be repaired via more error-prone
repair&nbsp;mechanisms. The resulting build-up of DSBs and erroneous DNA ultimately leads to cell death,
through a process called Synthetic Lethality.<sup data-ref="7-11">7-11</sup></li>
            </ul>
        </div><!-- end info -->
      
       <!-- navigation -->
        <div class="item nav hide"><span class="close icon"></span>
        	<ul class="section">
        		<li data-href="1"><span>Unmet need</span></li>
        		<li data-href="2"><span>Mechanism<br />of action</span>
                	<ul>
                		<li data-href="2"><span>PARPi</span></li>
                		<li data-href="3"><span>DNA repair</span></li>
                	</ul>
                </li>
        		<li data-href="4"><span>Clinical Data</span>
                	<ul>
                		<li data-href="4"><span>Extended PFS</span></li>
                		<li data-href="5"><span>Study overview</span></li>
                		<li data-href="6"><span>BRCAm<br />sub-analysis</span></li>
                		<li data-href="7"><span>TFST<br />Exploratory Analysis</span></li>
                		<li data-href="8"><span>TSST<br />Exploratory Analysis</span></li>
                		<li data-href="9"><span>Overall Survival</span></li>
                		<li data-href="10"><span><em>Post-Hoc</em> interim exploratory analysis of os</span></li>
                		<li data-href="11"><span>Patient Characteristics</span></li>
                	</ul>
                </li>
        		<li data-href="12"><span>BRCAm+</span>
                	<ul>
                		<li data-href="12"><span>BRCAm testing</span></li>
                		<li data-href="13"><span>About BRCAm</span></li>
                		<li data-href="14"><span>Testing<br />guidelines</span></li>
                		<li data-href="15"><span>BRCAm status</span></li>
                	</ul>
                </li>
        		<li data-href="16"><span>Patient<br />Support</span>
                	<ul>
                		<li data-href="16"><span>LYNPARZA Patient&nbsp;Access Programme</span></li>
                		<li data-href="17"><span>Patient&nbsp;Support Programme</span></li>
                		<li data-href="18"><span>Patient<br />Support Kit</span></li>
                		<li data-href="19"><span>Capsule<br />companion</span></li>
                	</ul>
                </li>
        		<li data-href="20"><span>Dosing &amp;<br />administration</span>
                	<ul>
                		<li data-href="20"><span>Safety and<br />tolerability</span></li>
                		<li data-href="21"><span>Dosing</span></li>
                	</ul>
                </li>
        		<li data-href="22"><span>Summary</span></li>
        	</ul>
            
        </div><!-- end nav -->
    </div>

    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/TimelineLite.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		 var mySwiper = new Swiper('.swiper-container', {
        	paginationClickable: true,
        	direction: 'vertical',
			nextButton: '.swiper-button-next',
        	prevButton: '.swiper-button-prev'
		  });
		 $('.indicator .arrow').on('tap', function(){ 
				$(this).toggleClass('less').prev('p').slideToggle();
		 })
		
	})

</script>
</body>
</html>
